Gujarat Themis Biosyn signs agreement to acquire Sanofi's global anti-TB and anti-infective portfolio of 13 brands across 55+ countries.
The €158 million cash transaction includes marketing authorizations and commercial rights for portfolio with €62 million 2025 net sales.
Acquisition enables forward integration into regulated markets, expected to be EPS accretive and close by Q3 FY27 end.
Strategic move strengthens GTBL's global pharmaceutical platform and leverages fermentation-based capabilities for higher margins.